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Introduction
Numerous protein and peptide pharmaceuticals such as recombinant human growth hormone, gaserelin acetate, leuprolide acetate and recombinant bovine somatropin have already received approval from regulating authorities worldwide 1 . However, there are many difficulties associated with delivering biopharmaceutical drugs. The oral route of administration of proteins results in substantial degradation and poor bioavailability 2 , therefore, parenteral delivery is usually preferred. However, proteins often exhibit short half-lives in serum, thus requiring frequent administration to maintain their plasma level 3 . To prolong the therapeutic level of proteins, controlled release is required and this can be achieved using biodegradable polymers 4 . A range of formulation methods have been utilized to encapsulate proteins in polymeric micro-and nanoparticles, but water-in-oil-in-water (w/o/w) emulsion solvent evaporation is the most frequently used method. Difficulties in the encapsulation of proteins are related to their high molecular weight (M W) , high water solubility and instability upon exposure to formulation conditions 5 . An initial burst release followed by slow, incomplete release of the native protein as a result of protein instability and aggregation has also been recognized as a major problem 6 . Interactions between the protein and the polymer also influence the release profile. These interactions are dependent on protein M W ; isoelectric point; amino acid composition; and hydrophobicity, as well as polymer M W and chemistry 1 . Polymer properties such as M W , copolymer composition and crystallinity can also be tailored to alter polymer degradation and subsequent drug release profiles 7, 8 . For example, an increase in the M W of Poly(lactic-co-glycolic acid) (PLGA) resulted in longer degradation times and slower release of bovine serum albumin and tetanus toxid 9, 10 . Bovine serum albumin (BSA) and lysozyme (LS) were encapsulated using two different M W s of PLGA by (w/o/w) solvent extraction and oil-in-oil (o/o) solvent evaporation systems 11 . BSA was efficiently encapsulated independently of PLGA M W , whereas the encapsulation of LS was favored with low M W PLGA.
Although the choice of polymer is critical, few new polymers have been developed for specific drug delivery applications, and mono-and copolymers of poly(lactic acid) (PLA) and poly(glycolic acid) (PGA) are commonly adopted due to their widespread availability and approval for human use. One alternative is to develop new polymeric delivery systems to release the protein and retain bioactivity over the required target period 12 .
A family of biodegradable polyesters with backbone functionality, synthesized via the enzyme catalyzed transesterification of a combination of activated diacids, glycerol and lactone monomers has been designed to overcome the lack of chemical functionality of the commonly used polyesters 13, 14 . The free hydroxyl group from the glycerol monomer allows for the attachment of chemical moieties such as pharmaceutically active drugs, hence introducing the potential for the controlled incorporation and release of desired molecules (drugs, proteins and peptides). In addition, the physical characteristics (hydrophilicity and hydrophobicity) of these polymers can easily be manipulated by varying the backbone chemistry 15 . Previously, poly(glycerol adipate) (PGA) and poly(glycerol adipate-co-o-pentadecalactone) (PGA-co-PDL) have been investigated for the delivery of dexamethasone phosphate 16 and ibuprofen 17 . More recently, PGA-co-PDL has shown promise as a sustained release carrier for pulmonary delivery using the model drug, sodium flourescein 18 . PGAco-PDL (1:1:1, M W 30.0 KDa) has also previously been used to prepare a-chymotrypsin (a-CH)-loaded microparticles via the double (w/o/w) emulsion solvent evaporation method 19, 20 . In the initial w/o emulsification step, a lipophilic surfactant is incorporated to aid the emulsification of the aqueous drug solution and the organic phase containing the polymer. Gaskell et al. found that on average 22.1 mg a-CH per 1 mg PGA-co-PDL was encapsulated, and there was a loss of enzyme bioactivity during encapsulation followed by a further gradual loss upon release 19 . The low amount of a-CH encapsulated is typical of these systems due to the diffusion of the protein from the inner to outer aqueous phases during particle formation and upon solvent evaporation. These different previous studies have all utilized a 1;1;1 ratio of monomers, and the M W of the particular polymers used varied depending upon the M W achieved during synthesis . Which, given the nature of these reactions, can be difficult to precisely control. It is therefore not known whether the copolymer composition or M W may influence the characteristics of the particles formed.
Polymer properties such as molecular weight Mw, copolymer composition and crystallinity can be tailored to alter polymer degradation and the consequent drug release profiles as well as the microparticles characteristics. The nature of the protein encapsulated can also affect the particle formation, loading, release and bioactivity profiles 21 .
Therefore this study is an extension of the work presented by Gaskell et al., examining the effect of small changes in polymer Mw and copolymer composition on the encapsulation efficiency, loading, particle size, morphology, in vitro release and bioactivity of two different proteins, a-CH (25 kDa) and LS (14 kDa). These enzymes differ in size (LS, 14 KDa, a-CH, 25 KDa), isoelectric point (LS, 11.2, a-CH, 9.1) and stability (LS is more stable than a-CH).
Materials and methods

Materials
Novozyme 435 (a lipase from Candida antarctica immobilized on a microporous acrylic resin) was purchased from Bio Catalytics (USA) and stored over P 2 O 5 at 5 C prior to use. Glycerol, 1.3propandiol, o-pentadecalactone, a-chymotrypsin (type II from bovine pancreas), lysozyme (from chicken egg white), aerosol OT (dioctyl sodium sulphosuccinate), poly(vinyl alcohol) (PVA, M W 9-10 KDa, 80% hydrolyzed), azocasein, 4-methylumbelliferyl b-D-N,N 0 ,N 00 -triacetylchitotrioside, citric acid, trichloroacetic acid (TCA) and sodium citrate were all obtained from Sigma-Aldrich Chemicals (UK). Dichloromethane and N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulphonic acid] (HEPES) were purchased from BDH (UK). Tetrahydrofuran (THF) was purchased from Fisher Scientific. Phosphate buffered saline tablets at pH 7.4 were obtained from Oxoid (UK). Divinyl adipate (DVA) was obtained from Fluorochem (UK). A polystyrene standards kit was purchased from Supelco (USA).
Polymer synthesis
The copolymers PGA-co-PDL and PPA-co-PDL were synthesized, processed and characterized using methods adapted from Thompson et al. 22 and further described by Gaskell et al. 19 Polymer M W was varied by controlling the reaction time. Reaction times of 6, 18 and 24 h were used to prepare PGAco-PDL (1:1:1) with a M W of 11.4, 26.0 and 39.2 KDa, respectively. The ratio of divinyl adipate (DVA) and glycerol (1:1) to o-pentadecalactone was varied to produce polymers theoretically containing 1:1:0.5 and 1:1:1.5 of DVA, glycerol and o-pentadecalactone, respectively. Using the same reaction conditions, PPA-co-PDL with a Mw of 22.0 KDa was synthesized from a 1:1:1 molar ratio of DVA: 1.3-propanediol: o-pentadecalactone over 24 h.
The polymers were characterized by gel permeation chromatography, GPC (Viscotek TDA Model 300 ran by OmniSEC3 operating software precalibrated with polystyrene standards) and 
Particle preparation
The multiple emulsion-solvent evaporation (w/o/w) technique was employed for the encapsulation of a-CH and LS as reported previously 19 . Briefly, a 1% (v/v) solution of protein (100 mg mL -1 ) in phosphate buffered saline (PBS) pH 7.4 was added dropwise to a homogenizing solution of polymer (30 mgmL -1 ) and aerosol AOT (2 mM) in dichloromethane (15 ml) and emulsified using a IKA yellowline DI 25 basic at 8000 rpm for 30-40 s. This first emulsion was then gradually added to a mixing 1% (w/v) PVA solution (135 ml). This w/o/w emulsion was left to mix with a Silverson L4 RT mixer at 1000 rpm for 3 h to allow for dichloromethane evaporation at 25 C. The particles obtained were collected by centrifugation (EBA 20, Hettich) at 6000 g for 6 min at room temperature. The supernatant was labeled ''wash 1'' and retained for further analysis. The microparticles were re-suspended in 120 ml PBS buffer to remove the residual PVA present on the surface of the particles and centrifuged as before. The collected supernatants were labeled ''wash 2''. The microparticles were then filtered, vacuum-dried overnight and stored in the fridge. Three batches of each type of particle were prepared. 
Particle characterization
The particles were visualized by scanning electron microscopy (FEI -Inspect S Low VAC Scanning Electron Microscope). A suspension of particles in water was deposited on 13 mm aluminum stubs layered with a sticky conductive carbon tab and air dried. An atomic layer of gold was deposited onto the particle containing stubs using an EmiTech K 550X Gold Sputter Coater, 25 mA for 3 min.
Particle size and size distribution were determined by a laser scattering device (Beckman Coulter LS 13 320, with aqueous liquid module) according to the method described by Pamujula et al. 23 The Frauenhofer method was used to calculate the size distribution of particles in water. The results obtained from measurements of at least three batches of microparticles were described by the volumetric mean diameter of the microparticles (VMD) in micrometers. Equation (1) gives the formula for the span of the volume distribution, which measures the width of the size distribution relative to the median diameter (d[v,50]). A more heterogeneous size distribution gives a large span value 24 .
Powder X-ray diffraction (PXRD) patterns were collected by using a Rigaku Miniflex X-ray diffractometer. Samples were finely ground and packed into an aluminum sample holder. Patterns were collected between 5 and 50 2, at increments of 0.02 2, scanning speed 2 min-1, voltage 30 KV, current 15 mA using CuKa (1.54 Å ) radiation.
Drug loading and encapsulation efficiency
The theoretical encapsulation efficiencies and enzyme loading from three different batches of microparticles were calculated from the measurement of the non-encapsulated protein fraction present in the wash samples (Equation 2) and with the assumption that no protein was lost during the preparation and processing of the particles 19 
In vitro release of enzyme from microparticles
Sacrificial sampling was used to observe the release of the enzyme from the particles. In a clean dry 1.5 ml microtube, 10 mg of vacuum-dried particles and 1 ml of phosphate buffer saline pH 7.4 at 37 C were placed under sink conditions. The microtubes were then incubated at 37 C in an orbital shaker (IKA KS 130) at 250 rpm. Samples were removed at increasing time points over 24 h and centrifuged (5 min at 13 500 rpm (17 000 g), accuSpin Micro 17) to collect the particles. The supernatants were retained for analysis by the protein assays described below. The bioactivity of both enzymes was presented as the bioactive fraction of the released enzyme. This was calculated from the ratio of enzyme concentration determined from enzyme activity and the total enzyme concentration as determined by UV spectroscopy using the methods described below 25 .
Methods for assessing protein content and activity
The encapsulation washes (wash 1 and 2) and supernatants from the release studies were analyzed for protein content 19 and activity using the following methods.
UV spectrophotometry
To determine the total protein content in a sample, the absorbance was measured at 282 nm for both a-CH and LS, (UV/VIS spectrophotometer Lambda 40, Perkin Elmer, run via the UV WinLab version 2.80.03 software).
Azocasein assay
The proteolytic activity of a-CH following release from particles was determined using a chromogenic-based technique as modified by Gaskell et al. 19 Briefly, 50 mL sample, standard or blank and 200 mL of azocasein (10 mg/ml), prepared in 25 mM HEPES buffer were incubated for 3 h at 37 C. The reaction was terminated by addition of 750 mL of 0.3 M trichloroacetic acid to precipitate the undigested protein-chromogenic conjugate and the samples were centrifuged for 5 min at 13 500 rpm (17 000 g) (accuSpin Micro 17) to remove the precipitate. Blank samples were prepared using deionized water to determine the amount of azo-dye released nonenzymatically from the substrate. Absorbance of the samples was recorded at 415 nm compared to blank reagent samples using UV/VIS spectrophotometer Lambda 40, Perkin Elmer, using the UV WinLab version 2.80.03 software. Three replicates of each sample were obtained and processed.
Muramidase assay
The muramidase activity of LS was determined using the method described by Telkov et al. 26 Supernatant (760 mL) was incubated with 8 mM 4-Methylumbelliferyl-b-D-N,N 0 ,N 00 -triacetylchitotrioside in 50 mM citrate buffer, pH 6.0, in the presence of 5 mM MgSO 4 for 3 h at 37 C. The fluorescence intensity was measured using a fluorescence spectrophotometer (Varian Cary Eclipse, operated via the Cary Eclipse Advanced Reads Application version 1.1 (132) software) at an excitation wavelength of 350 nm and an emission wavelength of 450 nm.
Statistical analysis
Statistical analysis was performed using student t-paired test. The F-test was used to test the significance of variance. The statistical significance level was set at p 0.05.
Results and discussion
The aim of this research was to investigate if changes to the M W and chemistry of PGA-co-PDL would alter the encapsulation, release and bioactivity of a-CH and LS loaded into microparticles fabricated by a w/o/w double emulsion solvent evaporation technique.
Polymer synthesis and characterization
The lipase catalyzed ring opening polymerization of an equimolar quantity of DVA, glycerol and o-pentadecalactone produced PGA-co-PDL (1:1:1) of different M W s (11.2, 26.0 and 39.2 KDa) by altering the time in contact with the lipase (6, 18 and 24 h, respectively) ( Figure 1) . A maximum M W for this type of polymer is usually obtained around 24 h synthesis followed by a subsequent decrease in M W as hydrolytic reactions dominate 27 . This means that the range and difference in M W s achievable is small and can be difficult to control. The incorporation of 1,3propandiol in place of the glycerol produced PPA-co-PDL (1:1:1, DOI: 10.3109/03639045.2013.814060
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A different set of polymers with a constant 1:1 ratio of DVA and glycerol, but with either 0.5 or 1.5 equivalents of o-pentadecalactone, was also prepared (1:1:0.5, M W 23.0 KDa and 1:1:1.45, M W 34.0 KDa). These polymers should be more (1:1:1.45) and less (1:1:0.5) hydrophobic than PGA-co-PDL (1:1:1) depending on the relative number of hydroxyl groups. It is difficult to control the M W of these polymers as an increase in the amount of o-pentadecalactone increases the polymer M W obtained. This means it can be difficult to directly compare the effect of monomer ratio on polymer and particle properties as there is also a difference in M W . 1 H-NMR integration patterns were used to confirm that the monomeric content in the polymers were as expected and comparable to that reported in previous work 22 . The difference in the number of protons at 1.34 is indicative of the different proportions of pentadecalactone within the polymer backbone (1:1:0.5 (11H), 1:1:1 (22H) and 1:1:1.45 (32H)).
Particle characterization
Protein-containing and blank particles containing no protein were prepared from each of the different polymers. The mean median of particle diameters (d 50 ) of three separate batches of a-CHor LS-loaded microparticles and the span values are presented in Table 1 .
The particle sizes obtained ranged between 9 and 18 mm. The particles prepared from PGA-co-PDL (1:1:0.5) were aggregated so no size data was obtained for this polymer. There was no significant difference observed between the sizes of most of the a-CHor LS-loaded particles for the different polymers used except with PGA-co-PDL (1:1:1, 39.2 KDa) where significantly larger LS-loaded particles were obtained (p50.05). Previously, it was reported that the higher the M W or concentration of polymer in the emulsion, the larger the diameter of the produced particles 28 . It was not anticipated that any great differences in particle size would be observed because the polymer M W range studied was small, and the stirring speed, solution concentrations and the organic phase volume were fixed which are the main contributing factors affecting particle size 20 . Additionally, analysis of the span values (see Table 1 ) indicates that all microparticles produced had a large size distribution which made it difficult to draw any real trends from the data obtained.
The morphology of microparticles is very important as it influences particle degradation and hence can affect the protein release 29 . Moreover, particle morphology is dependent on the nature, composition and M W of the polymer 30,31 as well as the particle formulation conditions 20 .
The SEM images of the external structure of a-CH loaded PGA-co-PDL microparticles prepared from PGA-co-PDL (1:1:1) of different M W are presented in Figure 2 (A-C). Almost spherical microparticles with a slightly irregular shape and a rough ridged surface were observed. A high variability in microparticle size was noted during the SEM analysis which supports the span value data shown in Table 1 . A similar morphology was also observed with LS-loaded microparticles fabricated from the same polymers ( Figure 2G-I) . Hence, changing either the polymer M W or the type of protein encapsulated did not alter the particle morphology.
Altering the chemistry did, however, have an effect on particle morphology. PGA-co-PDL (1:1:0.5) produced small, aggregated, non-uniform particles ( Figure 2D) , and increasing the lactone content within the polymer changed the particle morphology slightly. With both a-CHand LS-loaded PGA-co-PDL (1:1:1.45) particles, some of the particles appeared irregular in shape with rough surfaces, while the others were spherical with a slightly smoother surface than those prepared from PGA-co-PDL (1:1:1) ( Figure 2E and J) . These smooth particles were more similar to those obtained from PPA-co-PDL ( Figure 2F and K) . A similar morphology to a-CH-loaded microparticles was observed with the LS-loaded microparticles ( Figure 2H-K) . Thompson et al. reported similar morphological characteristics for particles prepared from PGA-co-PDL and PPA-co-PDL 22 . Drug-free and ibuprofen-loaded microspheres 17 produced using PGA-co-PDL were rough with a ridged morphology, whereas the equivalent PPA-co-PDL microspheres were smooth.
Drug loading and encapsulation efficiency
Polymer M W , degree of hydrophilicity, polymer chemistry, volume of organic phase and enzyme and polymer concentration play an important role in determining the amount of enzyme encapsulated. It was reported that increasing the M W of poly ("-caprolactone), PLA and PLGA increased the encapsulation efficiency and the mean particle size due to the increased viscosity of the organic phase, which reduces protein diffusion into the external aqueous phase before polymer hardening 8, 32 . Partitioning of the drug from the internal to the external aqueous phase limits the encapsulation efficiency and drug loading in particles prepared via the emulsion solvent evaporation technique. During particle formation, solvent removal and polymer precipitation can alter the amount of the protein that partitions into the external aqueous phase 33 . It was previously determined that 3 h was the optimum time for PGA-co-PDL protein-containing particle formation as this provided enough time for the solvent to evaporate yet minimized enzyme diffusion to the aqueous phase 19 .
The encapsulation efficiencies and enzyme loading from three different batches of microparticles prepared using different polymers are presented in Table 2 .
Increasing the M W of PGA-co-PDL had no significant effect on either the encapsulation efficiency or a-CH loading (p40.05). However, a shift in PGA-co-PDL M W from 11.4 to 39.2 KDa might not be large enough to induce a significant increase in the viscosity of the organic phase, leading to a change in enzyme loading. The degree of crystallinity of the polymer is another important factor affecting drug encapsulation as drugs will tend to be encapsulated in the amorphous region of the polymer 34 . Table 1 . The mean median of particle size and the span values for a-CHand LS-loaded microparticles prepared via the w/ o/w double emulsion solvent evaporation technique. The results are the mean of three different prepared batches AE S.D.
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Span values 397  398  399  400  401  402  403  404  405  406  407  408  409  410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462   463  464  465  466  467  468  469  470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526 527 528 Biodegradable microparticles for protein delivery 5   529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594 The PXRD patterns illustrated in Figure 3 indicate that both PGAco-PDL and PPA-co-PDL are semicrystalline copolymers. Both PGA-co-PDL and PPA-co-PDL showed characteristic peaks at 21.5 and 24 2. PGA-co-PDL of different M Ws have the same XRD patterns, indicating they have the same level of crystallinity, and this may explain the similar encapsulation efficiencies observed. However, the PXRD pattern for PPA-co-PDL has a flatter baseline between 0 and 20 2, indicating that it is a more crystalline material. This difference in degree of crystallinity between PGA-co-PDL and PPA-co-PDL may have influenced microparticle formation but does not explain the increased encapsulation efficiency observed with PPA-co-PDL. Furthermore, changing the polymer composition by altering the pentadecalactone monomeric ratio from 0.5 to 1.5 molar ratio significantly (p50.05) increased the encapsulation efficiency of LS-loaded microparticles. An increase was also observed with a-CH-loaded particles, but this was not significant (p40.05). Compared to PGA-co-PDL, utilizing the more hydrophobic polymer (PPA-co-PDL) a significant (p50.05) increase in encapsulation efficiency and a-CH loading (from 12.52 AE 4.42 to 38.58 AE 6.48% and 41.70 AE 0.01 to 128.50 AE 12.70, respectively) was observed. The highest a-CH and LS encapsulation efficiency and loading were obtained from the most hydrophobic polymer, PPA-co-PDL. These results suggest that the more hydrophobic polymers demonstrate better encapsulation efficiency and drug loading of both enzymes compared to the less hydrophobic variants.
Similarly, McGee et al. showed that ovalbumin-loaded microparticles prepared with PLGA with higher lactide to glycolide content (85:15) gave higher protein loading compared to the more hydrophilic one with 50:50 lactide to glycolide ratio 35 . Also, higher amounts of bovine albumin were encapsulated using PLGA (75:25) compared to the more hydrophilic PEGylated PLGA co-polymer 36 .
Comparing the encapsulation efficiencies and enzyme loading for both enzymes, it was found that LS showed a higher encapsulation and loading compared to a-CH with all the PGAco-PDL variants assessed ( Table 2) . LS is a smaller, positively charged enzyme that has the ability to be adsorbed onto the surface of polymers and this adsorption will affect its encapsulation and release kinetics 37 . Furthermore, as previously reported 37, 38 , the temperature rises during the emulsification steps and the adjustment of the pH to 7.4 can lead to favorable conditions for LS adsorbing onto polymers. This could result in increased amounts of LS being encapsulated within PGA-co-PDL.
Also, we cannot neglect that using 1% PVA as an emulsifier imparts a negative charge to the surface of PGA-co-PDL and PPA-co-PDL which would support enzyme binding. It was reported that PVA, which is physically entrapped within the surface layer of the polymer, imparts a negative surface charge on the microparticles produced 39, 40 . However, comparable amounts of 128.5 AE 12.7 and 121.33 AE 11.6 mg/mg particle of a-CH and LS were encapsulated, using PPA-co-PDL. This represents a significant increase over PGA-co-PDL for a-CHbut not LS-loaded particles.
In vitro release
It was anticipated that polymer M W and polymer backbone chemistry would be important factors affecting the drug release 21 .
Varying the M W , varies the degradation rate of the polymer and release kinetics of the drug can be controlled accordingly 41 . Additionally, the hydrophobicity of the polymer can affect the drug release by reducing the rate of water penetration into the microspheres and drug egress to some extent compared to the less hydrophobic polymers 42 . Furthermore, different particle morphologies may affect the protein release profile through its effect on the microspheres porosity and the distribution of the drug within the matrix 29, 43 .
The release profiles of either a-CH or LS under sink conditions from different batches are shown in Figures 4 and 5 . Figure 4 shows the release of a-CH from microparticles prepared using different polymers over 24 h into PBS buffered saline. Most of the a-CH-loaded microparticle formulations showed a biphasic release pattern with an initial high burst release phase followed by a continuous release phase for the first 5 h which became constant till the end of the release study. The extent of the burst release varied between different microparticle formulations, depending on the polymer used, and a notable difference was observed between PGA-co-PDL (1:1:1 26.0 KDa or 11 KDa) and the other polymers.
Other research groups 11, 33 have observed that increasing polymer M W led to a decrease in the total amount of enzyme released. In this study, there was no general trend observed between increasing M W and decreasing enzyme release, which may be because the differences in M W were small, but there was significantly less release after 24 h with PGA-co-PDL (39 KDa) particles compared to PGA-co-PDL (26 KDa or 11 KDa) particles. Varying the proportion of PDL within the polymer from 0.5 to 1.5 mole equivalents did not have any consistent effect on the 661  662  663  664  665  666  667  668  669  670  671  672  673  674  675  676  677  678  679  680  681  682  683  684  685  686  687  688  689  690  691  692  693  694  695  696  697  698  699  700  701  702  703  704  705  706  707  708  709  710  711  712  713  714  715  716  717  718  719  720  721  722  723  724  725  726   727  728  729  730  731  732  733  734  735  736  737  738  739  740  741  742  743  744  745  746  747  748  749  750  751  752  753  754  755  756  757  758  759  760  761  762  763  764  765  766  767  768  769  770  771  772  773  774  775  776  777  778  779  780  781  782  783  784  785  786  787  788  789  790  791  792 a-CH release from microparticles. The biggest difference in release was found when comparing PGA-co-PDL (26 KDa) with the more hydrophobic polymer of a comparable M W , PPA-co-PDL (22 KDa). Compared to PPA-co-PDL, PGA-co-PDL showed a significantly (p50.05) higher burst release of a-CH (20.13 AE 3.0% compared to 8.54 AE 2.7%) and a greater amount of release after 24 h in PBS buffer (45.28 AE 2.7% compared to 15.84 AE 4.5%). Furthermore, PPA-co-PDL demonstrated the lowest burst and total release of a-CH of all the prepared microparticles.
The initial burst release phase of a-CH from these microparticles could be due to the rapid release of protein near to the surface of microparticles which accumulates at the water/oil interface during the solvent evaporation process. The release of the protein entrapped within the polymeric matrix causes a continuous release of a-CH during the first 5 h. Furthermore, the constant release phase could be attributed to the protein aggregation and degradation that occurs during the release process. Despite the higher encapsulation efficiency gained from PPAco-PDL, these particles demonstrated a slower burst and continuous release rate compared with PGA-co-PDL with comparable Mw. This might be due to the higher hydrophobicity and slower rate of degradation of this polymer (unpublished data). The lower surface area available for contact with the dissolution medium and the large particle size could be other contributing factors toward this slow release as denser microparticles with smooth surfaces will usually produce a lower rate of initial release compared with rough, porous microparticles. This is in agreement with Thompson et al. who observed a similar effect for ibuprofen release from PGA-co-PDL and PPA-co-PDL microparticles 17 .
The release profiles of LS from the different polymeric microparticles are shown in Figure 5 . In this case, the LS-loaded microparticle formulations showed a very small initial burst phase followed by continuous release until the end of the release study at 24 h. With LS there was a general trend of increasing PGAco-PDL (1:1:1) M W and decreasing enzyme release. The release of LS from the 39 KDa polymer was significantly lower, and there was less difference observed between the 26 KDa and 11 KDa variants. Although, as with a-CH, there was a difference in the release of LS from PPA-co-PDL (22 KDa) and PGA-co-PDL (26 KDa) of a comparable M W, with LS the release profile of the PPA-co-PDL particles was virtually the same as that of PGAco-PDL (39 KDa). Biodegradable microparticles for protein delivery 7   793  794  795  796  797  798  799  800  801  802  803  804  805  806  807  808  809  810  811  812  813  814  815  816  817  818  819  820  821  822  823  824  825  826  827  828  829  830  831  832  833  834  835  836  837  838  839  840  841  842  843  844  845  846  847  848  849  850  851  852  853  854  855  856  857  858   859  860  861  862  863  864  865  866  867  868  869  870  871  872  873  874  875  876  877  878  879  880  881  882  883  884  885  886  887  888  889  890  891  892  893  894  895  896  897  898  899  900  901  902  903  904  905  906  907  908  909  910  911  912  913  914  915  916  917  918  919  920  921  922  923  924 It was observed that the pattern of LS release was different from that obtained with a-CH. a-CH release was characterized by an initial burst followed by a slow continuous release phase for the first 5 h then a plateau was reached. On the other hand, LS showed a lower burst release followed by a higher continuous release phase. This was especially evident with the lower M W PGA-co-PDL. The lower burst release could be attributed to the more efficient encapsulation of LS inside the microparticles with minimum amounts remaining adsorbed on the surface. Stronger binding of LS to these polymers could be another reason for this as LS is cationic and these particles have a slightly anionic surface from incomplete removal of PVA.
With all the microparticles studied, an incomplete release of enzyme from these was observed even after 3 weeks. This has been observed by many researchers, and it might be due to degradation of the protein during the manufacturing of the microparticles 44 . Formation of intermolecular linkages, hydrolysis of the protein molecule and the nonspecific adsorption between polymer and protein either physically or chemically can lead to protein degradation 45 .
Enzyme bioactivity
Retaining biological activity is crucial for the delivery of enzymes and peptides, and preservation of the tertiary structure is required to maintain activity. Enzyme activity before and after encapsulation and upon release can be monitored to investigate the effect of these processes on biological activity. Many researchers have estimated the bioactivity of LS by measuring the rate of degradation of Micrococcus luteus cells 25, 46 . However, this method is not always reproducible because of the dependence on the ionic strength of the medium 47, 48 . Different methods using small synthetic substrates have been developed, investigated and recommended for accurate determination of LS [49] [50] [51] .
Observation of the bioactive fraction of a-CH released from microparticles prepared using PGA-co-PDL and PPA-co-PDL ( Figure 6 ) indicates that the maximum bioactivity was observed at zero hours and ranged between 27% and 60%. This was followed by a sharp decrease in activity during release into PBS buffer (pH 7.4). It was noticed that a-CH released from PGA-co-PDL exhibited a maximum activity of between 40% and 60%, and PPAco-PDL showed the lowest activity of $27% at zero hour. Furthermore, a gradual loss in bioactivity was recorded for all the a-CH-loaded microparticles investigated. The reduction in activity of a-CH could be attributed to conformational changes in the a-CH active site during emulsification. The homogenization and use of organic solvents are considered important steps in causing protein deactivation and aggregation resulting in a low bioactive fraction at zero hour [52] [53] [54] . The gradual loss in activity during in vitro release was most likely due to autolysis and protein fragmentation 53 . This finding is similar to what was already reported by Gaskell et al. where they found that a-CH released from PGA-co-PDL-loaded microparticles lost its bioactivity gradually with an onset of loss due to proteolysis upon 2 h release 19 .
At zero hour of release, LS retained almost 100% of its initial bioactivity within all the particles investigated. Then, with time it began to gradually lose its bioactivity (Figure 7) . The higher M W polymer, PGA-co-PDL (1:1:1, 39.0 KDa), and the more hydrophobic polymers, PGA-co-PDL (1:1:1.45) and PPA-co-PDL, showed a significantly (p50.05) higher bioactive fraction, after 5 and 24 h release, compared to the other co-polymers. The maximum LS bioactive fraction was found using PGA-co-PDL LS is a relatively stable enzyme 55 which can better withstand the harsh condition of the emulsification process and this was confirmed by the retention of its bioactivity at zero time of release (bioactive fraction ranged from 0.9 to 1.03 for all the investigated polymers, Figure 7) . Similarly, it was reported by Giteau and coworkers that the LS released from PLGA microspheres was still biologically active compared to a-CH, peroxidase and b-galactosidase-loaded PLGA microspheres 57 Q1
. However, during in vitro release there was a gradual decrease in the bioactive fraction which could be attributed to the effect of PBS buffer on the released LS. So, the nature of the release medium on the enzyme activity is very important, as many proteins are not stable in buffer media at 37 C. However, for most studies the choice of release medium is dictated by the in vivo target for delivery of the enzyme. Jiang et al. investigated protein stability and proteinpolymer interactions in different release media and their effect on protein release profiles from PLGA microspheres using LS as a model protein 37 . They found that LS showed a higher stability at pH 4.0 acetate buffer and pH 2.5 glycine buffer, whereas at pH 7.4 PBS, the stability was low and significant protein adsorption was evident. Furthermore, the higher bioactive fraction of LS in PGAco-PDL (1:1:1, Mw, 39.2 KDa) and PGA-co-PDL (1:1:1.45) could possibly be attributed to the higher solubility of these polymers in DCM compared with PPA-co-PDL and the lower M W PGA-co-PDL polymers. Additionally, the longer the contact time of the enzyme in the organic phase, the more enzyme activity would be lost. Thus, a higher solidification rate would be beneficial in retaining the LS biological activity. Similar results were reported by Ghaderi and Carlfors regarding stability of LS during emulsification process within PLGA 48 . Future work will focus on enhancing macromolecule encapsulation efficiency as well as maintaining stability during the manufacturing process. For example, the use of additives to protect the protein structure or the application of alternative formulation methods such as spray drying or s/o/w emulsions may substantially reduce the loss in bioactivity during encapsulation.
Conclusion
This research has shown that altering the M W of PGA-co-PDL from 11.2 to 39.2 KDa had little impact on particle morphology, size, encapsulation efficiency or bioactivity of a-CHand LSloaded microparticles. Altering the polymer chemistry had a greater effect, as a higher encapsulation efficiency and drug loading of both a-CH and LS were obtained with PPA-co-PDL compared to PGA-co-PDL particles. A biphasic release pattern was obtained with all microparticles studied, and the release profiles varied according to the polymer used. A lower burst and continuous release was obtained for both enzymes with the more hydrophobic polymers, PPA-co-PDL and PGA-co-PDL (1:1:1.45) and with the higher M W PGA-co-PDL (39.2 KDa). Furthermore, a very low burst release was recorded with LS compared to a-CH with all the investigated polymers.
One benefit of the low impact of small changes in M W or PDL content on encapsulation and release is that batch-to-batch variations in the polymers should not have a demonstrable effect on either the properties of particles formed or the encapsulation and release data obtained. These findings suggest that more substantial changes to polymer properties are required to significantly influence the encapsulation and release of proteins. The nature of this type of polymerization reaction means that it is difficult to achieve higher M W materials and extend the range of M W s studied. Small changes to the polymer chemistry has been shown to have a greater effect, hence future studies will focus on further modifying the polymer chemistry either by incorporating different monomers into the backbone or via modification of the pendant hydroxyl groups.
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